490 related articles for article (PubMed ID: 26048605)
1. Intracranial bleedings in patients on long-term anticoagulant treatment: Benefits from oral thrombin and factor Xa inhibitors in clinical practice.
Łukasik M; Zawilska K; Undas A
Neurol Neurochir Pol; 2015; 49(3):171-9. PubMed ID: 26048605
[TBL] [Abstract][Full Text] [Related]
2. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
3. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
[TBL] [Abstract][Full Text] [Related]
4. Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation.
Weitz JI; Eikelboom J
Thromb Haemost; 2016 Jan; 115(2):257-70. PubMed ID: 26466666
[TBL] [Abstract][Full Text] [Related]
5. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
6. Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk.
Potpara TS; Lip GY
Prog Cardiovasc Dis; 2015; 58(2):177-94. PubMed ID: 26162958
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
Senoo K; Lip GY
Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
[TBL] [Abstract][Full Text] [Related]
8. Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials.
Vanassche T; Hirsh J; Eikelboom JW; Ginsberg JS
Thromb Haemost; 2014 Nov; 112(5):918-23. PubMed ID: 25187203
[TBL] [Abstract][Full Text] [Related]
9. Safety and effectiveness of oral factor Xa inhibitors versus warfarin in nonvalvular atrial fibrillation patients at high-risk for falls.
Miao B; Alberts MJ; Bunz TJ; Coleman CI
J Thromb Thrombolysis; 2019 Oct; 48(3):366-372. PubMed ID: 31228038
[TBL] [Abstract][Full Text] [Related]
10. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
Reddy P; Giugliano RP
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
[TBL] [Abstract][Full Text] [Related]
12. A review of oral anticoagulants in patients with atrial fibrillation.
Greenspon AJ
Postgrad Med; 2012 Nov; 124(6):7-16. PubMed ID: 23322134
[TBL] [Abstract][Full Text] [Related]
13. Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation.
Bisson A; Angoulvant D; Philippart R; Clementy N; Babuty D; Fauchier L
Adv Ther; 2017 Jun; 34(6):1283-1290. PubMed ID: 28493056
[TBL] [Abstract][Full Text] [Related]
14. Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta-analysis of randomized controlled trials.
Kwong JS; Lam YY; Yan BP; Yu CM
Cardiovasc Drugs Ther; 2013 Feb; 27(1):23-35. PubMed ID: 23224686
[TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence.
Martínez-Rubio A; Dan GA; Kaski JC
Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):933-47. PubMed ID: 24948333
[TBL] [Abstract][Full Text] [Related]
16. Practical considerations in the use of novel oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation.
Deitelzweig S
Cardiovasc Ther; 2014 Apr; 32(2):74-81. PubMed ID: 24119252
[TBL] [Abstract][Full Text] [Related]
17. To Bleed or Not to Bleed: That is the Question. The Side Effects of Apixaban.
Ciccone MM; Zito A; Devito F; Maiello M; Palmiero P
Curr Drug Targets; 2018; 19(6):581-584. PubMed ID: 26424386
[TBL] [Abstract][Full Text] [Related]
18. Novel oral anticoagulants in non-valvular atrial fibrillation.
Potpara TS; Lip GY
Best Pract Res Clin Haematol; 2013 Jun; 26(2):115-29. PubMed ID: 23953900
[TBL] [Abstract][Full Text] [Related]
19. A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens.
Providência R; Grove EL; Husted S; Barra S; Boveda S; Morais J
Thromb Res; 2014 Dec; 134(6):1253-64. PubMed ID: 25457584
[TBL] [Abstract][Full Text] [Related]
20. Meeting the unmet needs in anticoagulant therapy.
Weitz JI
Eur J Haematol Suppl; 2010 Jul; (72):1-28. PubMed ID: 20553560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
